1.50 / AMA PRA Category 1 CreditTM 1.50 / CPEU for Registered Dietitians/Registered Dietetic Technicians
Provided by Haymarket Medical Education
Supported by an educational grant from Sanofi US
Timely initiation and appropriate use of basal insulin can be critical elements in the care of patients with type 2 diabetes mellitus (T2DM). This activity focuses on use of the newer basal insulins whose pharmacokinetic and pharmacodynamic profiles better replicate endogenous patterns of insulin secretion compared with older agents in this class. The newer basal insulins are also associated with substantially lower risk for hypoglycemia, particularly nocturnal hypoglycemia.
Internal medicine physicians and other healthcare providers who manage the care of patients with type 2 diabetes mellitus
At the conclusion of this activity, participants should be better able to:
Identify patients with type 2 diabetes mellitus (T2DM) who are candidates for basal insulin use
Implement strategies to overcome patient and provider reluctance to initiate and advance insulin therapy
Differentiate among basal insulins with regard to their pharmacokinetic and pharmacodynamic profiles and how closely they can replicate insulin secretion in healthy individuals
Develop individualized treatment plans that minimize hypoglycemia risk in T2DM
Conflict Of Interest Disclosure Policy
In accordance with the ACCME Standards for Commercial Support, HME requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational activities.
Javier Morales, MD, FACP, FACE (Chair) Clinical Associate Professor of Medicine Hofstra Northwell School of Medicine at Hofstra University Hempstead, NY Vice President Advanced Internal Medicine Group, PC East Hills, NY
Dr. Morales receives consulting fees from and is on the speakers’ bureaus for Abbott Laboratories, Eli Lilly and Company, Janssen Pharmaceuticals, and Novo Nordisk Inc.
Daniel Einhorn, MD, FACP, FACE Medical Director Scripps Whittier Diabetes Institute San Diego, CA Clinical Professor of Medicine University of California, San Diego Clinical Endocrinologist Diabetes and Endocrine Associates La Jolla, CA
Dr. Einhorn receives consulting fees from Abbott Laboratories, Adocia, Eli Lilly and Company, Epitracker, GlySens Incorporated, Halozyme Therapeutics, Intarcia Therapeutics, Inc., Janssen Pharmaceuticals, Novo Nordisk Inc., Sanofi US, and Takeda Pharmaceutical Company. He also receives research grants from AstraZeneca, Bristol-Myers Squibb, Eisai Co., Ltd., Eli Lilly and Company, Janssen Pharmaceuticals, Mylan, Inc., Novo Nordisk Inc., and Sanofi US. Dr. Einhorn has ownership interests in Epitracker, GlySens Incorporated, Halozyme Therapeutics, and Nexus BioPharma, Inc.
Jeremy Pettus, MD Assistant Professor of Medicine Division of Endocrinology University of California, San Diego Director, Type 1 Diabetes Taking Control of Your Diabetes San Diego, CA
Dr. Pettus receives consulting fees from Dexcom, Inc., Insulet Corporation, MannKind Corporation, Novo Nordisk Inc., Sanofi US, and Valeritas, Inc., and is on the speakers’ bureau for Sanofi US.
Accredited Provider Disclosure
Haymarket Medical Education staff involved in the planning and content review of this activity have no relevant financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Haymarket Medical Education designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The following activity has been approved by the ACCME, whose approval is recognized by the Commission on Dietetic Registration and, as such, RDs/DTRs will be able to receive 1.50 CPEU.
Disclosure of Unlabeled Use
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Haymarket Medical Education and Sanofi US. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.